Anti-inflammatory drugs

Innovative anti-inflammatory drug

• A prodrug based on an indomethacin derivative (codename IML)
• Dosage form: parenteral, oral and topical
• Patent protection: Russian patent
• Indications for use: treatment of inflammatory and degenerative joint diseases (arthritis, osteoarthritis, gout)
• Main advantages: due to its prodrug mode of action and innovative technology of active agent delivery to the inflammation site, the new drug doesn’t have direct analogs in the world market and differs from market-present NSAIDs in the following:
  • minimal risk of serious adverse effects towards gastrointestinal tract;
  • high efficacy (anti-inflammatory and analgesic activity);
  • prolonged action
• Project stage: preclinical trials shall be finished in 2018

Project stage

---

Innovative anti-inflammatory drug

• Based on a new small molecule (codename LIS)
• New mechanism of action: inhibition of inducible NO synthase
• Patent protection: US, EU, Eurasian, Russian patents
• Indications for use: treatment of inflammatory and autoimmune diseases (including arthritis) with severe pain
• Main advantages:
  • the first drug of its class, iNOS inhibitor;
  • potent analgesic and anti-inflammatory activity;
  • highly effective in treating autoimmune arthritis;
  • no adverse effects towards gastrointestinal tract;
• Project stage: preclinical trials shall be finished in 2018

Project stage